Agrawal S. “Antisense oligonucleotides towards clinical trials”, Trends Biotechnol 14(10) 376-387 (1996). |
Akhter et al. “Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)”, Nuc Res 19 5551-5559 (1991). |
Alon et al. “Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity”, Na Med 1(10); 1024-1028 (1995). |
Atwood TK. “Genomics The Babel of bioinformatics”, Science 290(5491):471-473 (2000). |
Benjamin et al. “Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors, induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal”, Proc Natl Acad Sci USA 94(16):8761-8766 (1997). |
Berendsen, HJC. “A Glimpse of the Holy Grail?”, Science 282:642-643 (1998). |
Blaese RM, Gene Therapy for Cancer, Sci Am 276(6):111-115 (1997). |
Bouck et al. “How tumors become angiogenic” Adv Cancer Res 69:135-174 (1996). |
Bunn et al. “Oxygen sensing and molecular adaptation in hypoxia”, Phgysiol Rev 76:839-885 (1996). |
Burke et al. “Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors”, in Methods in Enzymology, vol 194, “Guide to Yeast Genetics and Molecular Biology”, eds Guthrie et al, Academic Press, Inc. Chap 17. pp 251-270 (1991). |
Calabretta et al. “Antisense strategies in the treatment of leukemias”, Semin Oncol 23:78 (1996). |
Capecchi, “Altering the genome by homologous recombination”, Science 244:1288-1292 (1989). |
Carmeliet et al, “Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis”, Nature 394(66923):485-490 (1998). |
Crooke ST, “Progress in antisense therapeutics”, Hematol Pathol 9(2):59-72 (1995). |
Davies et al, “Targeted alterations in yeast artificial chromosomes for inter-species gene transfer”, Nucleic Acids Res 20(11) 2693-2698 (1992). |
de Gruyter, Concise Encyclopedia Biology, p 32. |
Dickinson et al, “High frequency gene targeting using insertional vectors”, Hum Mol Genet 2(8):1299-1302 (1993). |
Duff et al, “Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells”, Research Advances in Alzheimer's Disease and Related Disorders (1995). |
Duke et al, “Cell Suicide in Health and Disease”, Sci Am 275(6):80-87 (1996). |
Eckstein, “Nucleotide Phosphorothioates”, Ann Rev Biochme 54:367-402 (1985). |
Felgner, “Nonviral Strategies for Gene Therapy”, Sci Am 276(6)102-106 (1997). |
Fyodorov et al, et-1, a novel ETS domain factor that can activate neuronal nAchR gene transcription, J Neurobiol 34(2) 151-163 (1998). |
Gallagher et al. “Identification of p53 Genetic Suppressor Elements which Confer Resistance to Cisplatin”, Oncogene 14 185-193 (1997). |
Galperin et al, “Who's your neighbor? New computational approaches for functional genomics”, Nat Biotechnol 18(6):609-613 (2000). |
Gewritz, “Oligodeoxynucleotide-based therapeutics for human leukemias”, Stem Cells Day 11:96 (1993). |
Gordon JW. “Transgenic Animals”, Intl Rev Cytol 115:171-229 (1989). |
Hanahan et al, “Patterns and Emerging Mechanisms of Angiogenic Switch During Tumorigenesis” Cell 86:353-364 (1996). |
Hanania et al, “Recent advances in the application of gene therapy to human disease”, Am J Med 99 537 (1995). |
Herskowitz, “Functional Inactivation of Genes by Dominant Negative Mutations”, Nature 329(6136):219-222 (1987). |
Holzmayer et al, “Isolation of Dominant Negative Mutants and Inhibitory Antisense RNA Sequences by Expression Selection of Random DNA Fragments”, Nucleic Acids Res l 20(4):711-717 (1992). |
Huxley et al. “The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion”. Genomics 9:742-750 (1991). |
Iyer et al, J Org Chem 55:4693-4699 (1990). |
Jakobovits et al, “Germ-line transmission and expression of a human-derived yeast artificial chromosome”, Nature 362 255-261 (1993). |
Kato et al, “Expression of the Vascular Endothelial Growth Factor (VEGF) Receptor Gene, KDR, in Hematopoietic Cells and Inhibitory Effect of VEGF on Apoptotic Cell Death Caused by Ionizing Radiation”, Cancer Res 55:5687-5692 (1995). |
Lamb et al, “Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice”, Nat Genet 5 22-29 (1993). |
Lavitrano et al, “Sperm Cells as vectors for introducing foreign DNA into eggs genetic transformation of mice”, Cell 57:717-723 (1989). |
Lefebvre-D'Hellencourt et al, “Immunomodulation by cytokine antisense oligonucleotides” Eur Cytokine Netw 6:7 (1995). |
Lev-Lehman et al, “Antisense Oligomers in vitro and in vivo”. in Antisense Therapeutics, Cohen et al, ed, Plenum Press (New York, 1997)s. |
Lo CW, “Transformation by iontophoretic microinjection of DNA: multiple integrations without tandem insertions”, Mol Cell Biol 3(10):1803-1814 (1983). |
Loke et al, “Characterization of oligonucleotide transport into living cells”, Proc Natl Acad Sci USA 86:3474 (1989). |
Mansour SL. “Gene targeting in murine embryonic stem cells: Introduction of specific alterations into the mammalian genome”, Genet Anal Tech Appl 7(8):219-227 (1990). |
Morrison RS, “Suppression of basic fibroblast growth factor expression by antisense oligonucleotides inhibits the growth of transformed human astrocytes”, J Biol Chem 266:728 (1991). |
Niinaka et al, “Expression and Secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells”, Cancer Res 58(12) 2667-2674 (1998). |
Nomura et al, “Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and Pericytes”, J Biol Chem 270(47) 28316-28324 (1995). |
O'Rourke et al, “Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR Role of hypoxia-inducible factor-1”, Eur J Biochem 241 403-410 (1996). |
Pearson et al, “Expression of the human β-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice”, Proc Natl Acad Sci USA 90:10578-10582 (1993). |
Rosolen et al, “Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line”, Cancer Res 50:6316-6322 (1990). |
Rothstein, “Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast”, in Methods in Enzymology, vol. 194, “Guide to Yeast Genetics and Molecular Biology”, Guthrie et al. eds. Academic Press, Inc (1991). Chapt 19. pp 281-301. |
Scanlon et al. “Oligonucleotides-mediated modulation of mammalian gene expression”, FASEB J 9:1288 (1995). |
Schedl et al, “A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice”, Nature 362:258-261 (1993). |
Shaw et al, “Modified deoxyoligonucleotides stable to exonuclease degradation in serum”, Nucleic Acids Res 19:747-750 (1991). |
Soker et al, “Inhibition of Vascular Endothelial Growth Factor (VEF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF 169” J Biol Chem 272(50):31582-31588 (1997). |
Spitzer et al, “Inhibition of deoxynucleases by phosphorothioate groups in oligodeoxyribonucleotides”. Nucleic Acids Res 18 11691-11704 (1988). |
Strauss et al, “Germ line transmission of a yeast artificial chromosome spanning the murine alpha 1(l) collagen locus”, Science 259:1904-1907 (1993). |
Thompson et al, “Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells”, Cell 56:313-321 (1989). |
Uhlmann et al, “Antisense Oligonucleotides: A New Therapeutic Principle”, Chem Re 90(4):543-584 (1990). |
Van Der Putten et al, “Efficient insertion of genes into the mouse germ line via retroviral vectors”, Proc Natl Acad Sci U S A 82(18):6148-6152 (1985). |
Wagner et al, “Potent and selective inhibition of gene expression by an antisense heptanucleotide”, Nat Biotechnol 14:840-844 (1996). |
Wagner RW, “Gene inhibition using antisense oligodeoxynucleotides”, Nature 372:333 (1994). |
Watanabe et al, “Tumor cell autocrine mobility factor is the neuroleukin/phosphohexose isomerase polypeptide”, Cancer Res. 56(13):2960-2963 (1996). |
Whitesell et al, “Episome-generated N-myc antisense RNA restricts the differentation potential of primitive neuroectodermal cell liens”, Mol Cell Biol. 11:360 (1991). |
Woolf et al, “The stability toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos”, Nucleic Acids Res 18:1763-1769 (1989). |
Wright et al, “Antisense Molecules and Their Potential for the Treatment of Cancer and AIDs”, Cancer J 8:185-189 (1995). |
Yakubov et al, “Mechanism of oligonucleotide uptake by cells involvement of specific receptors?”, Proc Natl Acad Sci USA 86(17) 6454-6458 (1989). |